Primaquine plus clindamycin as a promising salvage therapy for Pneumocystis jirovecii pneumonia: A retrospective analysis in Japanese patients

• Published in: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2021-06, Vol.27 (6), p.924-928
• Main Authors: Koga, Michiko, Suganuma, Akihiko, Kikuchi, Tadashi, Yoshimura, Yukihiro, Shoji, Kensuke, Kobayashi, Ichiro, Takezaki, Shunichiro, Kato, Yasuyuki, Kimura, Mikio, Maruyama, Haruhiko
• Format: Article
• Language: English
• Subjects: Effectiveness; Pneumocystis pneumonia; Primaquine-clindamycin; Salvage therapy; Tolerability
• ISSN: 1341-321X; 1437-7780
• DOI: 10.1016/j.jiac.2021.03.001

Treatment of intractable Pneumocystis jirovecii pneumonia (PCP) patients with primaquine (PQ) in combination with clindamycin (CLDM) was conducted by the Research Group on Chemotherapy of Tropical Diseases (RG-CTD), as a kind of compassionate use. Primaquine was not nationally licensed at the time but imported by RG-CTD for the use in a clinical research to investigate safety and efficacy in malaria treatment. Eighteen Japanese adult patients thus treated were analyzed. Prior to the treatment with PQ-CLDM, most of the patients had been treated with trimethoprim-sulfamethoxazole first, all of which being followed by pentamidine and/or atovaquone treatment. This combination regimen of PQ-CLDM was effective in 16 (89%) patients and developed adverse events (AEs) in five (28%) patients. AEs included skin lesions, methemoglobinemia, and hepatic dysfunction, though none of them were serious. As a second-line or salvage treatment for PCP, PQ-CLDM appears to be a better option than pentamidine or atovaquone. Currently in Japan, both PQ and CLDM are licensed drugs but neither of them is approved for treatment of PCP. Considering the potentially fatal nature of PCP, approval of PQ-CLDM for treating this illness should be urged.